Industry Supported Sessions - ESGO 2017 Vienna

Industry Supported Sessions

Saturday, November 4, 2017

13:00 -14:30

Hall B

THE KEY ROLE OF QUALITY OF LIFE IN THE LONG-DISTANCE RACE OF OVARIAN CANCER

Symposium Organized by: PharmaMar

CHAIR: Andreas Du Bois, Germany

13:00   WELCOME AND INTRODUCTION
Andreas Du Bois, Germany

13:05   SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
Felix Hilpert, Germany

13:25    BEING PRACTICAL

Case 1:  Isabelle Ray-Coquard , France
Case 2:  Nicoletta Colombo, Italy
Case 3: Christian Marth, Austria

 

14.25     CLOSING AND REMARKS
Andreas Du Bois, Germany

 

17:00 -18:00

Hall A

NEW PERSPECTIVES ON PARP INHIBITION

Symposium Organized by: TESARO

CHAIRS: Christian Marth, Austria and Andreas du Bois, Germany

17:15  WELCOME AND INTRODUCTION

Christian Marth, Austria

17:20  RECURRENT OVARIAN CANCER: WHAT DOES MAINTENANCE THERAPY
OFFER?
Nicoletta Colombo, Italy

17:35  WHICH PATIENTS WITH RECURRENT OVARIAN CANCER CAN BENEFIT FROM PARP INHIBITOR MAINTENANCE  THERAPY AND FOR HOW LONG?
Susana Banerjee, UK

17:55  HOW TO USE NIRAPARIB IN RECURRENT OVARIAN CANCER AND THE IMPACT ON PATIENT QUALITY OF LIFE
Mansoor Mirza, Denmark

18:10  CONCLUSION
Andreas du Bois, Germany

 

Sunday, November 5, 2017

07:30 – 08:30

Hall M

FIRST CLINICAL EXPERIENCES WITH NIRAPARIB

Symposium Organized by: TESARO

CHAIR: Jalid Sehouli, Germany

07:30 Introduction
Jalid Sehouli, Germany

07:40  Practical experiences from Klinik für Gynäkologie, Die
Charité – Universitätsmedizin Berlin, Germany
Jacek Grabowski, Germany

08:00  Discussion - Q & A

08:05  Practical experiences from CTCA at Southeastern Regional
Medical Center, Georgia USA
John P. Geisler, USA

08:25  Discussion - Q & A

08:30  Close

 

13:00 – 14:30

Hall A

FRONT-LINE OVARIAN CANCER: CAN WE DO BETTER?
TODAY, TOMORROW

Symposium Organized by: Roche

CHAIR: Sandro Pignata, Italy
With a multidisciplinary expert tumour board, this interactive and educational session will review the progress that has been made with front-line ovarian cancer treatment, including neoadjuvant and adjuvant therapy, surgery, and targeted treatments.

Chaired by Sandro Pignata, the tumour board will discuss the key considerations to have and main challenges faced when making front-line decisions for ovarian cancer; and consider ways in which we can do better for patients - now and in the future.

 

16:00 – 17:00

Hall A

HPV vaccination - Lessons Learned and the Future

Symposium Organized by: Merck

CHAIR: Elmar Joura, Austria

16:00  Welcome and Opening Remarks
Elmar Joura, Austria

16:05  From a 4vHPV to 9vHPV Vaccine—Setting Aspirations for the Future
Elmar Joura, Austria

16:25  HPV vaccination experience in prevention of recurrence
Alessandro Ghelardi, Italy

16:40  HPV Vaccination Population Coverage
Xavier Bosch, Spain

16:50  Q and A

 

Hall B

VIDEO TEACHING SESSION: “THE FUTURE OF PELVIC SURGERY: MAXIMIZING PATIENT OUTCOMES AND QOL

Symposium Organized by: ETHICON

CHAIR: Jalid Sehouli, Germany

16:00    PELVIC SIDE WALL SURGERY AND COMPLICATIONS
Jalid Sehouli, Germany

16:20    PELVIC NERVE SPARING TECHNIQUES AND COMPLICATIONS
Vito Chiantera, Italy

16:40    PELVIC VASCULAR SURGERY AND COMPLICATIONS
Santiago Domingo, Spain

 

Monday, November 6, 2017

13:00-14:30

Hall B

Bringing clarity to PARP inhibitor use in ovarian cancer

Symposium Organized by: AstraZeneca

CHAIR: Nicoletta Colombo, Italy

13:00    CLARITY THROUGH UNDERSTANDING – ADDRESSING PATIENT NEEDS

13:05    WELCOME AND INTRODUCTION
Nicoletta Colombo, Italy

13:10    TARGETING THE DNA DAMAGE RESPONSE – CLARIFYING THE RATIONALE FOR PARP INHIBITION
Rebecca Kristeleit, UK

13:25    MAINTAINING CONTROL WITH PARP INHIBITORS
Nicoletta Colombo, Italy

13:40    MAINTAINING CONTROL WITH PARP INHIBITORS
Nicoletta Colombo, Italy

13:40    PARP INHIBITORS – TRANSLATING EVIDENCE TO CLINICAL PRACTICE
Philipp Harter, Germany

13:55    TAILORED TREATMENT – SELECTING THE RIGHT PATIENT FOR PARP INHIBITION
Nicoletta Colombo, Italy

14:10    ILLUMINATION SESSION

All

14:25    SUMMARY AND CLOSE
Nicoletta Colombo, Italy

 

16:00 -17:00

Hall B

IMMUNOTHERAPY: NEW STRATEGIES FOR THE TREATMENT OF CERVICAL CANCER

Symposium Organized by: ADVAXIS

CHAIR: Christian Marth, Austria

16:00  OPENING AND INTROCUTION OF SPEAKER PANEL
Christian Marth, Austria

16:05  MOA OF THE IMMUNOTHERAPY AXALIMOGENE FILOSLISBAC (AXAL)
AND COMPARISON TO OTHER IMMUNOTHERAPIES
Sandro Pignata, Italy

16:20  PHASE 3 CLINICAL TRIAL OF AXAL IN COMBINATION WITH PD-1 IN
METASTATIC CERVICAL CANCER
Christian Marth, Austria

16:35  AXAL CLINICAL DATA IN METASTATIC CERVICAL CANCER
Sharad Ghamande, USA

16:50  Q&A

 

Hall C

PARP Inhibition and Ovarian Cancer: Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Symposium Organized by: Prime Oncology

CHAIR: Nicoletta Colombo, Italy

16:00  Welcome and introduction
Nicoletta Colombo, Italy

16:02  Introductory quiz
Nicoletta Colombo, Italy

16:05  Everything a clinician needs to know about DNA repair and PARP inhibition
Thomas Helleday, Sweden

16:20  A new string to the bow in the treatment of advanced ovarian cancer
Bradley Monk, USA

16:35  Clinical application of PARP inhibitors: Proactive management of adverse events
Rebecca Kristeleit, United Kingdom

16:45  Q&A and faculty discussion

16:53  PARP inhibition and ovarian cancer: Have we convinced you?
Nicoletta Colombo, Italy

16:58  prIME PointsTM
Nicoletta Colombo, Italy

17:00  Adjourn

You may also like

ESGO_2015_24102015_0296_WEB

Congress Highlights

 

 

Read More

DSC_5524

Vienna Landmarks

 

 

Read More

DSC_5637

Hotels in Vienna

 

 

Read More

register

Early Registration

 

 

Read More